Parkwalk invests in UK companies that are commercialising research and technology that has spun out from a UK university or research-intensive institution. We believe this distinct asset class has the ability not only to generate attractive investment returns but also positive returns for UK plc, and broader society.
The technologies we back have normally been incubated over several years in their respective university, have been peer reviewed and are IP-protected, sitting at the cutting edge of innovation and creating solutions to real-world challenges. The current portfolio employs over 1,500 highly skilled people, and have over 2,000 patent families protecting their products and know-how.
The knowledge creation and trickle-down impact of the portfolio company work on society is impossible to quantify. But there have been leaps forward in med-tech, cleantech, AI / machine learning, disease diagnosis, interpretation of genomic data, gene therapies etc as a result of our investments.
The UK is a world leader in terms of R&D with approximately 1% of the world’s population but 16% of the mostly highly cited research papers
The UK is a university superpower with four of the 10 top-rated universities in the world, five of the top 20 and ten of the top 50
Adjusted for the size of their economies, the UK now exceeds the US in number of spinouts formed, disclosures of discoveries, patents and licenses
Government expenditure on Research & Development is set to expand to 2.4% of GDP as the UK looks to builds a new modern industrial base
Emerging asset class
We believe that after two decades of expansion in mobile and web technologies, we are now at the start of a new trend of deeper technologies that will impact all industries and create immense value
This has been heightened by the professionalisation of this asset class over the last 10-20 years as universities look to capitalise on the R&D and IP incubated within the research institutions for many years before emerging into a new company
We invest in UK companies that are commercialising technology that has spun out from a British university or research institution. The technology is well tested and IP-protected, sitting at the cutting edge of innovation and creating solutions to real-world challenges
We invest in global sectors of strategic importance to UK Plc, such as life sciences, AI and quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech and big data
Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.
Refeyn has developed the world’s most sensitive light microscope enabling mass photometry as a revolutionary new way to measure molecule mass. The technology is based on detecting light scattered by single molecules in solution to generate a high-quality movie of single biomolecules as they approach the surface of a glass slide. The molecular mass of each
Salunda develops robust condition monitoring solutions for oilfield machinery, drilling and metering. The products are non-invasive, contactless and have no moving parts to enable them to operate in harsh environments. Products include the Latch Hawk pipe handling safety monitors and MudChecker drilling fluid analyser.
VersedAI, a University of Cambridge spin-out, is developing an advanced supervised deep learning solution that will allow companies to better understand significant business risk associated with their supply chains. The company’s technology uses advanced supervised deep learning methods combined with VersedAI’s own proprietary training data set to extract supply chain information from unstruct